Teplizumab approval for type 1 diabetes in the USA

Lancet Diabetes Endocrinol. 2023 Feb;11(2):78-80. doi: 10.1016/S2213-8587(22)00384-9. Epub 2023 Jan 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Diabetes Mellitus, Type 1* / drug therapy
  • Humans
  • Hypoglycemic Agents

Substances

  • Antibodies, Monoclonal, Humanized
  • Hypoglycemic Agents
  • teplizumab